search
Back to results

Hemolysis in Patients With Hereditary Spherocytosis (HS)

Primary Purpose

Hereditary, Hemolysis

Status
Unknown status
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
fermented papaya preparation (FPP)
Sponsored by
Wolfson Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Hereditary focused on measuring Hemolysis in Patients with Hereditary Spherocytosis, with documented family history of HS., spherocyte morphology,, splenomegaly and non-immune mediated hemolysis.

Eligibility Criteria

5 Years - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • patients > 5 years
  • with documented family history of HS
  • patients should have clinical and laboratory findings, consistent with mild to severe HS, diagnosed on the basis of spherocyte morphology, elevated MCHC (33-38 g/dl), with a mean value of (35.47 g/dl), increased osmotic fragility , splenomegaly and non-immune mediated hemolysis.

Exclusion Criteria:

  • non

Sites / Locations

  • Wolfsson Medical Center

Arms of the Study

Arm 1

Arm Type

No Intervention

Arm Label

Patients with Hereditary Spherocytosis

Arm Description

All patients should have clinical and laboratory findings, consistent with mild to severe HS, diagnosed on the basis of spherocyte morphology, elevated MCHC (33-38 g/dl), with a mean value of (35.47 g/dl), increased osmotic fragility , splenomegaly and non-immune mediated hemolysis.

Outcomes

Primary Outcome Measures

ROS, reduced glutathione (GSH) and lipid peroxides will be measured in RBC
ROS, reduced glutathione (GSH) and lipid peroxides will be measured in RBC following incubation with with 100 μM 2'-7'-dichlorofluorescin diacetate, 40 μM [1-(4-chloromercuryphenyl-azo-2-naphthol)] and fluor-DHPE, respectively for ROS [8] and with mercury orange for GSH [9]. After being washed twice, the cells will be resuspended in PBS and analyzed by flow cytometry .

Secondary Outcome Measures

Hemolysis
Hemolysis will be assayed by suspending 3 ml of packed RBC in PBS or in the autologous plasma and overnight incubation in the presence of various concentrations of antioxidants such as fermented papaya preparation (FPP)

Full Information

First Posted
September 12, 2010
Last Updated
September 13, 2010
Sponsor
Wolfson Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT01201174
Brief Title
Hemolysis in Patients With Hereditary Spherocytosis (HS)
Official Title
Oxidative Stress Contributes to Hemolysis in Patients With Hereditary Spherocytosis (HS) and Can be Ameliorated by Fermented Papaya Preparation (FPP)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2010
Overall Recruitment Status
Unknown status
Study Start Date
September 2010 (undefined)
Primary Completion Date
September 2011 (Anticipated)
Study Completion Date
September 2011 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
Wolfson Medical Center

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
In the present study the investigators are going to explore the oxidative status of HS-RBC and its contribution to hemolysis
Detailed Description
The oxidative status of cells, which is determined by the balance between pro-oxidants, such as the reactive oxygen species (ROS), and antioxidants, is a major regulator of cellular functions. Impaired balance between pro- and antioxidants causes oxidative stress which may result in oxidation of proteins, lipids and DNA with the final outcome of premature cell aging and apoptosis [1,2]. Oxidatively stressed red blood cell (RBC) have been observed in various congenital and acquired hemolytic anemias, including thalassemia, sickle cell anemia, congenital dyserythropoietic anemia, G6PD deficiency and paroxysmal nocturnal hemoglobinuria (PNH) as well as in myelodysplastic syndrome (MDS). Although the primary etiology is different in these anemias, oxidative stress mediates several of their pathologies, mainly hemolysis [3]. Hereditary Spherocytosis (HS) is a genetic disorder of the RBC skeleton with primary deficiency in spectrin, ankyrin-1, band 3 or protein 4.2 associated with chronic hemolytic anemia [4]. Secondary protein deficiencies resulting from oxidative stress are often observed and may be involved in the clinical manifestations of the disease [5].

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hereditary, Hemolysis
Keywords
Hemolysis in Patients with Hereditary Spherocytosis, with documented family history of HS., spherocyte morphology,, splenomegaly and non-immune mediated hemolysis.

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
15 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Patients with Hereditary Spherocytosis
Arm Type
No Intervention
Arm Description
All patients should have clinical and laboratory findings, consistent with mild to severe HS, diagnosed on the basis of spherocyte morphology, elevated MCHC (33-38 g/dl), with a mean value of (35.47 g/dl), increased osmotic fragility , splenomegaly and non-immune mediated hemolysis.
Intervention Type
Other
Intervention Name(s)
fermented papaya preparation (FPP)
Intervention Description
Hemolysis will be assayed by suspending 3 ml of packed RBC in PBS or in the autologous plasma and overnight incubation in the presence of various concentrations of antioxidants such as fermented papaya preparation (FPP) at 37oC in humidified atmosphere of 5% CO2 in air (10). Following 5 min centrifugation at 800 rpm, the supernatants will collected for Hb determination by measuring the absorbance at 540 nm.
Primary Outcome Measure Information:
Title
ROS, reduced glutathione (GSH) and lipid peroxides will be measured in RBC
Description
ROS, reduced glutathione (GSH) and lipid peroxides will be measured in RBC following incubation with with 100 μM 2'-7'-dichlorofluorescin diacetate, 40 μM [1-(4-chloromercuryphenyl-azo-2-naphthol)] and fluor-DHPE, respectively for ROS [8] and with mercury orange for GSH [9]. After being washed twice, the cells will be resuspended in PBS and analyzed by flow cytometry .
Time Frame
year
Secondary Outcome Measure Information:
Title
Hemolysis
Description
Hemolysis will be assayed by suspending 3 ml of packed RBC in PBS or in the autologous plasma and overnight incubation in the presence of various concentrations of antioxidants such as fermented papaya preparation (FPP)
Time Frame
year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: patients > 5 years with documented family history of HS patients should have clinical and laboratory findings, consistent with mild to severe HS, diagnosed on the basis of spherocyte morphology, elevated MCHC (33-38 g/dl), with a mean value of (35.47 g/dl), increased osmotic fragility , splenomegaly and non-immune mediated hemolysis. Exclusion Criteria: non
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ghoti Hossam, doctor
Phone
035028110
Email
drghoti123@yahoo.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
GHOTI HOSSAM, doctor
Organizational Affiliation
HEMATOLOGY DEPARTMENT ON WOLFSSON MEDICAL CENTER
Official's Role
Principal Investigator
Facility Information:
Facility Name
Wolfsson Medical Center
City
Holon,
State/Province
Israel,
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
GHOTI HOSSAM, doctor
Phone
970-35028110
Email
drghoti123@yahoo.com

12. IPD Sharing Statement

Learn more about this trial

Hemolysis in Patients With Hereditary Spherocytosis (HS)

We'll reach out to this number within 24 hrs